Qualigen’s AS1411 cancer drug candidate uses synthetic DNA, known as an aptamer, to target and destroy tumor cells, without the serious side effects associated with other cancer therapies. In addition, in vitro studies recently performed at the University of Louisville demonstrated that AS1411 may protect cells from the harmful effects of SARS-CoV-2 infection (COVID-19).
News 
Market Data 
Discover 
